Madrigal Pharmaceuticals (MDGL) Net Cash Flow Growth (5y) (2015 - 2026)
Madrigal Pharmaceuticals (MDGL) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn |
| 10 | Madrigal Pharmaceuticals | 16.16 Bn | 15.93 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.65% |
| Dec 31, 2025 | -11.95% |
| Sep 30, 2025 | 18.30% |
| Jun 30, 2025 | 20.42% |
| Mar 31, 2025 | 33.19% |
| Dec 31, 2024 | -25.40% |
| Sep 30, 2024 | -77.11% |
| Jun 30, 2024 | -47.21% |
| Mar 31, 2024 | 122.77% |
| Dec 31, 2023 | 14.39% |
| Sep 30, 2023 | 41.80% |
| Jun 30, 2023 | -16.64% |
| Mar 31, 2023 | -14.58% |
| Dec 31, 2022 | 14.94% |
| Sep 30, 2022 | 17.90% |
| Jun 30, 2022 | -16.19% |
| Mar 31, 2022 | 20.59% |
| Dec 31, 2021 | -26.19% |
| Sep 30, 2021 | 27.69% |
| Jun 30, 2021 | 11.10% |